Cargando…

Lipid mediators in diabetic nephropathy

The implications of lipid lowering drugs in the treatment of diabetic nephropathy have been considered. At the same time, the clinical efficacy of lipid lowering drugs has resulted in improvement in the cardiovascular functions of chronic kidney disease (CKD) patients with or without diabetes, but n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srivastava, Swayam Prakash, Shi, Sen, Koya, Daisuke, Kanasaki, Keizo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159383/ https://www.ncbi.nlm.nih.gov/pubmed/25206927 http://dx.doi.org/10.1186/1755-1536-7-12

Ejemplares similares

MicroRNAs in Kidney Fibrosis and Diabetic Nephropathy: Roles on EMT and EndMT
por: Srivastava, Swayam Prakash, et al.
Publicado: (2013)

Interactions among Long Non-Coding RNAs and microRNAs Influence Disease Phenotype in Diabetes and Diabetic Kidney Disease
por: Srivastava, Swayam Prakash, et al.
Publicado: (2021)

Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy
por: Srivastava, Swayam Prakash, et al.
Publicado: (2021)

N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition
por: Nagai, Takako, et al.
Publicado: (2014)

Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen
por: Nitta, Kyoko, et al.
Publicado: (2016)

Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs
por: Srivastava, Swayam Prakash, et al.
Publicado: (2020)

Editorial: Receptor Biology and Cell Signaling in Diabetes
por: Srivastava, Swayam Prakash, et al.
Publicado: (2022)

Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis
por: Srivastava, Swayam Prakash, et al.
Publicado: (2016)

Editorial: Receptor biology and cell signaling in diabetes: volume II
por: Srivastava, Swayam Prakash, et al.
Publicado: (2023)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis
por: Kanasaki, Keizo, et al.
Publicado: (2013)

Sirtuins and renal diseases: relationship with aging and diabetic nephropathy
por: Kitada, Munehiro, et al.
Publicado: (2012)

Endothelial SIRT3 regulates myofibroblast metabolic shifts in diabetic kidneys
por: Srivastava, Swayam Prakash, et al.
Publicado: (2021)

Editorial: Combating Diabetes and Diabetic Kidney Disease
por: Srivastava, Swayam Prakash, et al.
Publicado: (2021)

Cancer biology in diabetes
por: Sen, Shi, et al.
Publicado: (2014)

Autophagy as a Therapeutic Target in Diabetic Nephropathy
por: Tanaka, Yuki, et al.
Publicado: (2012)

SIRT3 deficiency leads to induction of abnormal glycolysis in diabetic kidney with fibrosis
por: Srivastava, Swayam Prakash, et al.
Publicado: (2018)

FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N-acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway
por: Li, Jinpeng, et al.
Publicado: (2017)

CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology
por: Kawakita, Emi, et al.
Publicado: (2021)

Loss of Mitochondrial Control Impacts Renal Health
por: Srivastava, Swayam Prakash, et al.
Publicado: (2020)

Diabetic angiopathy and angiogenic defects
por: Xu, Ling, et al.
Publicado: (2012)

Biology of Obesity: Lessons from Animal Models of Obesity
por: Kanasaki, Keizo, et al.
Publicado: (2011)

The Role of Ubiquitination and Sumoylation in Diabetic Nephropathy
por: Gao, Chenlin, et al.
Publicado: (2014)

Dietary Restriction Ameliorates Diabetic Nephropathy through Anti-Inflammatory Effects and Regulation of the Autophagy via Restoration of Sirt1 in Diabetic Wistar Fatty (fa/fa) Rats: A Model of Type 2 Diabetes
por: Kitada, Munehiro, et al.
Publicado: (2011)

Deficiency in catechol-o-methyltransferase is linked to a disruption of glucose homeostasis in mice
por: Kanasaki, Megumi, et al.
Publicado: (2017)

A low-protein diet exerts a beneficial effect on diabetic status and prevents diabetic nephropathy in Wistar fatty rats, an animal model of type 2 diabetes and obesity
por: Kitada, Munehiro, et al.
Publicado: (2018)

Dipeptidyl peptidase-4 plays a pathogenic role in BSA-induced kidney injury in diabetic mice
por: Takagaki, Yuta, et al.
Publicado: (2019)

microRNA Crosstalk Influences Epithelial-to-Mesenchymal, Endothelial-to-Mesenchymal, and Macrophage-to-Mesenchymal Transitions in the Kidney
por: Srivastava, Swayam Prakash, et al.
Publicado: (2019)

Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors
por: Kanasaki, Megumi, et al.
Publicado: (2011)

AMP-Activated Protein (AMPK) in Pathophysiology of Pregnancy Complications
por: Kumagai, Asako, et al.
Publicado: (2018)

The Relevance of the Renin-Angiotensin System in the Development of Drugs to Combat Preeclampsia
por: Ueki, Norikazu, et al.
Publicado: (2015)

Combat Diabetic Nephropathy: From Pathogenesis to Treatment
por: Gohda, Tomohito, et al.
Publicado: (2014)

Epigenetic regulation of core genes linking to diabetic nephropathy progression: Lesson from FinnDiane type 1 diabetes study
por: Makino, Hirofumi, et al.
Publicado: (2023)

Inhibition of Dipeptidyl Peptidase-4 Activates Autophagy to Promote Survival of Breast Cancer Cells via the mTOR/HIF-1α Pathway
por: Kawakita, Emi, et al.
Publicado: (2023)

Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon
por: Kanasaki, Keizo, et al.
Publicado: (2019)

N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes
por: Kanasaki, Keizo, et al.
Publicado: (2014)

Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner
por: Kitada, Munehiro, et al.
Publicado: (2017)

Autophagy: A Novel Therapeutic Target for Diabetic Nephropathy
por: Kume, Shinji, et al.
Publicado: (2015)

Rodent models of diabetic nephropathy: their utility and limitations
por: Kitada, Munehiro, et al.
Publicado: (2016)

Linagliptin ameliorated cardiac fibrosis and restored cardiomyocyte structure in diabetic mice associated with the suppression of necroptosis
por: Adhikari, Juthi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6t2r1bj80lr9i2jkhcmtjngoah